Moderna Stock News

CAMBRIDGE, MA / ACCESSWIRE / April 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 2, 2024 to report its f

Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

AI could solve one of the biggest problems in drug development: the lengthy time it takes to bring a product to market. The AI in healthcare market is set to expand at a compound annual growth rate of

Moderna and Merck are collaborating on a personalized cancer vaccine. That vaccine program just disclosed some new data from the clinic.

Moderna (MRNA) closed the most recent trading day at $107.01, moving -0.12% from the previous trading session.

There are some pharma stocks to sell in April. Holding these companies is too risky, especially as the industry faces increasing regulatory scrutiny and pricing pressures.

Biotech stocks are one of the hottest investing opportunities in the stock marketlately. The optimism surrounding the industry is evident in the SPDR S&PBiotech ETF's (NYSEARCA: XBI ) 25% bump in valu

Moderna's decision aligns with its broader effort to cut costs by resizing its Covid vaccine manufacturing footprint.

Data from an early-stage study shows that treatment with Moderna's (MRNA) experimental cancer therapy achieved positive clinical response in patients with a specific type of head and neck cancer.

Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

'Mad Money' host Jim Cramer looks at today's market winners and losers.

Moderna (MRNA) shares jumped Tuesday after the biotech firm reported positive results from a small trial involving those with head and neck cancers treated with its experimental individualized MRNA ca

Major U.S. equities made little headway in the session preceding the release of Consumer Price Index (CPI) report for March.

Moderna Inc.'s stock jumped 6% Tuesday to lead S&P 500 gainers, after the company shared cancer-vaccine data that suggests it may work in indications outside its target of melanoma.

Moderna Inc (NASDAQ: MRNA) popped as much as 10% on Tuesday after a Jefferies analyst made upbeat remarks on new data for its experimental vaccine for head and neck cancer.